Fulcrum Therapeutics, Inc. (FULC)
Stock Price:
$9.86 USD
-0.07 (-0.70%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
270.68M |
| Revenue (ttm) |
2.75M |
| Net Income (ttm) |
-67.60M |
| Shares Out |
27.45M |
| EPS (ttm) |
-14.92 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$9.86 |
| Previous Close |
$9.93 |
| Change ($) |
-0.07 |
| Change (%) |
-0.70% |
| Day's Open |
9.85 |
| Day's Range |
9.46 - 9.97 |
| Day's Volume |
111,196 |
| 52-Week Range |
5.72 - 22.96 |
More Stats
| Market Cap |
270.68M |
| Enterprise Value |
137.85M |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.45M |
| Float |
13.60M |
| EPS (basic) |
-0.24 |
| EPS (diluted) |
-14.92 |
| FCF / Share |
-2.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.15M |
| Short Ratio |
4.70 |
| Short % of Float |
8.43% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
98.43 |
| PB Ratio |
2.20 |
| Revenue |
2.75M |
| Operating Income |
-68.22M |
| Net Income |
-67.60M |
| Free Cash Flow |
-47.94M |
| Net Cash |
132.83M |
| Net Cash / Share |
4.84 |
| Gross Margin |
100.00% |
| Operating Margin |
-2,480.58% |
| Profit Margin |
-2,458.10% |
| FCF Margin |
-1,743.13% |
| ROA |
-40.60% |
| ROE |
-76.09% |
| ROIC |
-235.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (6)
| Buy |
4 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
1 |
| Sell |
0 |
Price Target
$18.50*
(87.63% upside)
Low
11.0
Current: $9.86
High
25.0
Target: 18.50
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -84.22 | -33.50 | -22.99 |
| Net Income | -82.68 | -32.59 | -22.96 |
| Shares Outstanding | 11.05 | 1.26 | 0.71 |
| Earnings Per Share | -8.13 | -31.14 | -35.68 |
| Operating Cash Flow | -39.48 | -22.56 | -20.07 |
| Capital Expenditures | -0.85 | -8.98 | -1.91 |
| Free Cash Flow | -40.34 | -31.54 | -21.98 |
| Cash & Equivalents | 97.81 | 73.89 | 0.41 |
| Net Cash / Debt | 97.81 | 73.89 | 0.41 |
| Assets | 110 | 85.77 | 4.34 |
| Liabilities | 23.29 | 9.77 | 3.02 |
| Book Value | 87.15 | -63.67 | -33.27 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Fulcrum Therapeutics, Inc. |
| Country |
United States |
| Employees |
73 |
| CEO |
Robert J. Gould |
Stock Information
| Ticker Symbol |
FULC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FULC |
| IPO Date |
July 18, 2019 |
Description
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of duchenne muscular dystrophy, friedreich ataxia, myotonic dystrophy 1, and a-synucleinopathies, as well as neurological and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.